Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Other Accumulated Expenses (2016 - 2025)

Aptevo Therapeutics' Other Accumulated Expenses history spans 10 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 4.62% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, up 4.62%, while the annual FY2024 figure was $1.3 million, 13.66% up from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $1.5 million at Aptevo Therapeutics, up from $948000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.6 million in Q3 2021 and bottomed at $30000.0 in Q2 2022.
  • The 5-year median for Other Accumulated Expenses is $1.1 million (2025), against an average of $1.2 million.
  • The largest annual shift saw Other Accumulated Expenses plummeted 96.96% in 2022 before it surged 2386.67% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $2.1 million in 2021, then crashed by 47.17% to $1.1 million in 2022, then grew by 3.63% to $1.1 million in 2023, then rose by 13.66% to $1.3 million in 2024, then increased by 15.1% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Other Accumulated Expenses are $1.5 million (Q3 2025), $948000.0 (Q2 2025), and $1.1 million (Q1 2025).